Memphasys Ltd Cash Flow Conversion Efficiency
Memphasys Ltd cash flow conversion efficiency. Based on the latest financial reports, Memphasys Ltd (MEM) has a cash flow conversion efficiency ratio of -0.306x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.23 Million ≈ $-871.57K USD) by net assets (AU$4.02 Million ≈ $2.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Memphasys Ltd (2008–2025)
Cash flow conversion efficiency of Memphasys Ltd from 2008 to 2025. This chart illustrates how Memphasys Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MEM share price today for real-time trading data and today's change.
Memphasys Ltd Cash Flow Conversion Ratio Explained
Memphasys Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Memphasys Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Memphasys Ltd ranked by their cash flow conversion efficiency. Also see market cap of Memphasys Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telecom Plus PLC
LSE:TEP
|
0.263x |
|
Chicago Rivet & Machine Co
NYSE MKT:CVR
|
0.032x |
|
Euro Tech Holdings Company Ltd
NASDAQ:CLWT
|
0.047x |
|
Umpas Holding AS
IS:UMPAS
|
-0.256x |
|
Grande Asset Hotels and Property Public Company Limited
BK:GRAND
|
-0.037x |
|
Millennium Silver Corp
V:MSC
|
0.019x |
|
Metal Hawk Ltd
AU:MHK
|
-0.079x |
|
Omineca Mining and Metals Ltd
V:OMM
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Memphasys Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Memphasys Ltd from 2008 to 2025. Review MEM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.37 Million ≈ $3.80 Million |
AU$-2.41 Million ≈ $-1.71 Million |
-0.449x | +5.01% |
| 2024-06-30 | AU$6.84 Million ≈ $4.84 Million |
AU$-3.23 Million ≈ $-2.29 Million |
-0.473x | -148.09% |
| 2023-06-30 | AU$7.38 Million ≈ $5.23 Million |
AU$-1.41 Million ≈ $-995.31K |
-0.190x | -567.12% |
| 2022-06-30 | AU$7.65 Million ≈ $5.41 Million |
AU$311.82K ≈ $220.63K |
0.041x | +685.09% |
| 2021-06-30 | AU$8.61 Million ≈ $6.09 Million |
AU$44.71K ≈ $31.63K |
0.005x | -57.84% |
| 2020-06-30 | AU$9.76 Million ≈ $6.90 Million |
AU$120.19K ≈ $85.05K |
0.012x | +110.57% |
| 2019-06-30 | AU$6.07 Million ≈ $4.30 Million |
AU$-707.47K ≈ $-500.58K |
-0.117x | +47.11% |
| 2018-06-30 | AU$3.35 Million ≈ $2.37 Million |
AU$-738.42K ≈ $-522.48K |
-0.220x | -107.21% |
| 2017-06-30 | AU$-402.24K ≈ $-284.61K |
AU$-1.23 Million ≈ $-869.31K |
3.054x | +455.22% |
| 2016-06-30 | AU$1.48 Million ≈ $1.05 Million |
AU$-1.27 Million ≈ $-899.02K |
-0.860x | +73.50% |
| 2015-06-30 | AU$746.59K ≈ $528.26K |
AU$-2.42 Million ≈ $-1.71 Million |
-3.244x | -442.08% |
| 2014-06-30 | AU$-992.85K ≈ $-702.50K |
AU$-941.64K ≈ $-666.27K |
0.948x | +771.03% |
| 2013-06-30 | AU$6.99 Million ≈ $4.95 Million |
AU$-987.97K ≈ $-699.05K |
-0.141x | +1.56% |
| 2012-06-30 | AU$4.56 Million ≈ $3.23 Million |
AU$-655.09K ≈ $-463.52K |
-0.144x | +40.80% |
| 2011-06-30 | AU$7.00 Million ≈ $4.95 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.243x | -18.49% |
| 2010-06-30 | AU$12.84 Million ≈ $9.09 Million |
AU$-2.63 Million ≈ $-1.86 Million |
-0.205x | +79.64% |
| 2009-06-30 | AU$-398.47K ≈ $-281.94K |
AU$400.62K ≈ $283.46K |
-1.005x | +72.30% |
| 2008-06-30 | AU$1.10 Million ≈ $779.28K |
AU$-4.00 Million ≈ $-2.83 Million |
-3.630x | -- |
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more